Business Information
The company principal activity is the development of proprietary iodine-based pharmaceutical agents and antimicrobials. Currently in the development stage, the company concentrates on the development of a proposed product application for the treatment for fibrocystic breast disease. The company has developed a proprietary iodine technology that maximizes the therapeutic index of iodine. The oral dosage form of the technology, called iogen (TM), generates molecular iodine in situ in the stomach of the patient. The company has also co-developed a bovine teat sanitizer, marketed as iodozyme(R), with west agro inc of Kansas city. The principal market for iodozyme is dairy farms. On 28-May-2004, the company acquired certain assets of mimetix inc.
|
|
Name |
Title
|
Email
|
| Paul Desjourdy | Dir., CEO, CFO, Pres., General Counsel, Treasurer | N/A | | Jack Kessler | Chmn., Chief Scientific Officer, Sec. | N/A | | Eugene Lieberstein | Dir. | N/A | | James Richards | Dir. | N/A | | Richard Maradie | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 40 | (3,047) | | 2005 | 450 | (646) | | 2004 | 160 | (2,647)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
